Citi raised the firm’s price target on Biogen (BIIB) to $185 from $180 and keeps a Neutral rating on the shares. The firm adjusted targets in the biopharma group as part of a Q4 preview. Estimates that are “beatable” and lower policy risk should create a favorable setup in 2026 for the group, the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIIB:
- Eisai, Biogen announces FDA accepted to review the sBLA for lecanemab-irmb
- Biogen sees Q4 pre-tax charge of $222M, or $1.26 per share
- Balanced Risk/Reward Keeps Biogen at Hold Amid Slower Leqembi Upside, MS Erosion, and Uncertain Pipeline
- Biogen Advances Presymptomatic SMA Strategy With New Salanersen Trial
- Biogen announces EU approval for high dose regimen of Spinraza for SMA